[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-cancer":26},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,520,0,25,[9,52,87,115,154,183,206,231,257,278,302,331,349,380,410,432,455,509,529,552,572,605,635,653,670],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":35,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100633240","study-of-high-precision-evaluation-of-molecular-residual-disease-through-a-platform-for-cancer-tracking-and-interception-sherlock-100633240",false,"NCT07524114","Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)","SHERLOCK","Inclusion Criteria:\n\n1. Patients with histopathological confirmation of cancer. Patients whose diagnosis are made by cytology may also be considered for this study. For tumor types that are typically diagnosed using unequivocal imaging findings or biomarker profiles (e.g. hepatocellular cancer, uveal melanoma), they can be eligible without histopathological or cytological confirmation.\n2. Patients must have cancer that is planned for or has undergone curative intent treatment (e.g. surgery, definitive radiation, definitive chemoradiation, adjuvant radiation, adjuvant chemotherapy, adjuvant chemoradiation, etc). Curative intent treatment must be completed within 12 months of study entry. For patients on adjuvant\u002Fmaintenance endocrine or biological therapy (e.g. bevacizumab, immunotherapy, etc), enrollment within 12 months of completion of curative intent treatment is allowed.\n3. Patient must be ≥ 18 years old.\n4. All patients must have signed and dated an informed consent form.\n\nExclusion Criteria:\n\n1\\. History of another active invasive cancer within 2 years prior to study enrolment. Exceptions include squamous and basal cell carcinoma of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the investigator, is considered cured with minimal risk of recurrence within 2 years.","ALL","18 Years",{"count":20,"type":21},7000,"ESTIMATED","OBSERVATIONAL","This study will collect, annotate, and sequence biospecimens (blood, tissue, urine, saliva and surgery drainage) from patients across different cancer types to detect molecular residual disease (MRD). Imaging scans and clinical data will also be gathered. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types. Results of ctDNA testing will be provided for clinical decisions and to determine eligibility for other linked interventional interception therapeutic studies, each of which will have a separate protocol.",[25,26,27,28,29,30,31,32,33,34],"Breast Cancer","Lung Cancer","Melanoma","Gynecologic Cancer","Genitourinary Cancer","Pancreatobiliary Cancer","Gastrointestinal Cancer","Head and Neck Cancer","Rare Cancer","Unknown Primary Tumors",[36,37,38],"Minimal Residual Disease","Liquid Biopsy","Circulating Tumor DNA","RECRUITING","2026-08-19",{"date":42,"type":43},"2026-08-21","ACTUAL",{"date":45,"type":43},"2026-03-31",{"date":47,"type":21},"2031-03-31",{"name":49,"class":50},"University Health Network, Toronto","OTHER",1,{"id":53,"slug":54,"hasResults":12,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":72,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":51},"100610399","dosing-physical-activity-among-older-cancer-survivors-who-experience-chronic-pain-a-micro-randomized-trial-100610399","NCT07227077","Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial","An Adaptive Design for Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial","Inclusion Criteria:\n\n1. Age greater than or equal to 65 years.\n2. Patients with a history of bladder, breast, cervical, colorectal, endometrial, lung, and prostate cancer diagnosis and treatment.\n3. Fluent in spoken and written English.\n4. Patient has access to smartphone\n5. Ability to understand a written informed consent document, and the willingness to sign it.\n\nExclusion Criteria:\n\n1. Patient has metastatic disease.\n2. Patient has cancer recurrence.","65 Years",{"count":61,"type":21},50,"INTERVENTIONAL",[64],"NA","The purpose of this study is to assess the best time to deliver a message to increase physical activity and how often participants will experience a pain episode in the 24 hours following their receipt of a message to increase physical activity.",[25,67,68,69,70,26,71],"Cervical Cancer","Bladder Cancer","Colorectal Cancer","Endometrial Cancer","Prostate Cancer",[73,74,75,76,77,78],"Physical Activity","Exercise","Survivorship","Supportive Care","Pain","Symptom Management",{"date":80,"type":43},"2026-08-20",{"date":82,"type":43},"2026-02-07",{"date":84,"type":21},"2027-05-01",{"name":86,"class":50},"Medical College of Wisconsin",{"id":88,"slug":89,"hasResults":12,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":94,"sex":17,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":62,"phases":99,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":51},"100605907","a-community-health-worker-intervention-to-improve-lung-cancer-screening-uptake-in-community-health-centers-100605907","NCT07168629","A Community Health Worker Intervention to Improve Lung Cancer Screening Uptake in Community Health Centers","CHATS","Inclusion Criteria:\n\n* Adults between the age of 50 and 80.\n* Potentially eligible for LCS according to the Electronic Health Record smoking history.\n* Receive their primary care at Mason Square, High Street, or Brightwood community health centers.\n* English- or Spanish- speaking.\n\nExclusion Criteria:\n\n* Not eligible for lung cancer screening based on age (age \\\u003C 50 or \\> 80 years) or smoking history (has not smoked more than 20 pack-years of tobacco cigarettes or quit more than 15 years ago).\n* Have received a lung cancer screen in the past.",true,"50 Years","80 Years",{"count":98,"type":21},80,[64],"Lung cancer screening (LCS) can reduce lung cancer-related mortality by 20%, but only 5-10% of eligible individuals have received an initial LCS. The goal of this study is to partner with community stakeholders to jointly develop and pilot test a multi-component community health worker-delivered intervention targeting key barriers to improve LCS and tobacco treatment utilization. The proposed activities will lay the groundwork for a subsequent R01 grant, conducting a fully powered randomized clinical trial to establish CHWs as an evidence-based practice that will facilitate access to screening and tobacco treatment, to reduce lung cancer mortality.",[26,102],"Tobacco Use",[104,105,106,107],"lung cancer screening","tobacco treatment","community health workers","community health centers",{"date":42,"type":43},{"date":110,"type":43},"2026-05-10",{"date":112,"type":21},"2028-08-01",{"name":114,"class":50},"Baystate Medical Center",{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":62,"phases":124,"briefSummary":126,"conditions":127,"keywords":134,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":153},"100529338","a-study-of-her3-dxd-in-subjects-with-locally-advanced-or-metastatic-solid-tumors-100529338","NCT06172478","A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors","HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria\n\nParticipants must meet all of the following criteria to be eligible for enrollment into the study:\n\n1. Sign and date the informed consent form prior to the start of any study-specific qualification procedures. A separate tissue screening consent will be obtained from all subjects to meet the baseline tumor tissue requirement.\n2. Participants aged ≥18 years (follow local regulatory requirements if the legal age of consent for study participation is \\>18 years old).\n3. Has locally advanced unresectable or metastatic disease (not curable by surgery or radiation) as follows:\n\n   Cutaneous (acral and non-acral) melanoma\n   1. Histologically or cytologically confirmed cutaneous (acral or non-acral) melanoma\n   2. Disease progression while on or after having received treatment with ≥1 prior line of anti-programmed cell death protein (PD-1) or anti-programmed death-ligand 1 (PD-L1) based therapy (previous use of other immune checkpoint inhibitors \\[ICIs\\] \\[ie, anti-CTLA4, anti- LAG-3\\] is acceptable). Prior anti-PD-(L)1 therapy in the adjuvant setting is allowed if there is recurrence within 12 weeks of the last dose. If the participant had BRAFm melanoma, they must have had disease progression on BRAF\u002FMEK inhibitor therapy as well.\n\n      Squamous cell carcinomas of the head and neck\n   3. Squamous cell carcinoma of the head and neck (with a primary location of oral cavity,oropharynx, larynx, hypopharynx) that is human papillomavirus (HPV) positive or negative (as determined by local standard). Excludes tumor location in the nasopharynx, nasal cavity, paranasal sinuses, and unknown primary locations.\n   4. Disease progression after having received treatment with ≥1 and \\\u003C3 prior lines of systemic therapy in the unresectable recurrent or metastatic setting.\n\n      Must have had disease progression on anti-PD-(L)1 (either as monotherapy or in combination with chemotherapy or other therapies). Must also have had disease progression on a platinum-based chemotherapy (PBC) regimen either in the recurrent or metastatic setting or in the locally advanced setting with curative intent.\n\n      Gastric or GEJ adenocarcinoma\n   5. Tumor tissue must be confirmed as negative for HER2 expression (immunohistochemistry \\[IHC\\] 0\u002F1+ or IHC 2+\u002Fin situ hybridization negative) as classified by American Society of Clinical Oncology\u002FCollege of American Pathologists (ASCO-CAP) guidelines and determined prior to enrollment by assessment in a local laboratory that is Clinical Laboratory Improvement Amendments certified (US sites) or accredited based on specific country regulations.\n   6. Disease progression after having received treatment with ≥2 prior lines of therapy that include PBC with or without anti-PD-1 therapy.\n\n      Ovarian Carcinoma\n   7. Pathologically documented high-grade serous epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.\n   8. Documented disease progression ≥4 weeks after the last dose of PBC and \\\u003C6 months of last dose of PBC in the advanced or metastatic setting. Prior use of folate reductase alpha targeting antibody-drug conjugate (ADC) (ie, mirvetuximab soravtansine) is allowed.\n\n      Cervical Cancer\n   9. Pathologically or cytologically documented recurrent or persistent squamous, adenosquamous, or adenocarcinoma of the uterine cervix.\n   10. Disease progression after having received ≥1 line of systemic therapy in the recurrent or metastatic setting. This may include prior anti-PD-(L)1 treatment and\u002For tissue factor directed ADC (tisotumab vedotin \\[TV\\]) per regional standard of care.\n\n       Endometrial Cancer\n   11. Pathologically or cytologically documented endometrial cancer (carcinoma of any histological sub-type or endometrial carcinosarcoma), irrespective of microsatellite instability (MSI) or mismatch repair (MMR) status.\n   12. Documented disease progression after having received ≥1 prior line of therapy (maximum of 3) PBC containing systemic treatment and an anti-PD(L)-1 therapy-containing regimen (combined or sequential) in the advanced\u002Fmetastatic setting.\n\n       Bladder Cancer\n   13. Pathologically or cytologically documented locally advanced\u002Funresectable or metastatic urothelial carcinoma of the bladder, renal pelvis, ureter, or urethra. Histological variants are allowed if urothelial histology is predominant. Small cell\u002Fneuroendocrine tumors are not allowed even if mixed histology.\n   14. Relapsed or progressed after treatment with ≥1 prior line of therapy (maximum of 3) that contains anti-PD-(L)1 therapy in the perioperative or metastatic setting. At least 1 line of therapy must also contain one of the following treatment modalities: chemotherapy or enfortumab vedotin. Prior fibroblast growth factor receptor (FGFR)-inhibitor treatment for those who are eligible are allowed.\n\n       * Required treatments can be given in combination or sequentially\n       * Prior cisplatin-based therapy or PD-(L)1 inhibitor therapy given for the treatment of muscle invasive urothelial carcinoma is counted as 1 line of therapy\n       * The same regimen administered twice in different disease settings will be counted as 1 line of prior therapy\n       * Participants in the second-line setting who have previously received enfortumab vedotin and pembrolizumab in combination can be enrolled.\n\n       Esophageal Carcinoma\n   15. Pathologically or cytologically documented esophageal squamous cell carcinoma.\n   16. Must have documented disease progression after having received 2 prior lines of therapy including previous PBC with or without an anti-PD-1 therapy-containing regimen (combined or sequential) in the advanced\u002Fmetastatic setting.\n\n       Pancreatic Carcinoma\n   17. Pathologically or cytologically documented unresectable or metastatic pancreatic adenocarcinoma.\n   18. Relapsed or disease progression after having received 1 prior line of systemic therapy in the locally advanced\u002Fmetastatic setting.\n\n       Prostate Cancer\n   19. Pathologically or cytologically documented unresectable locally advanced or metastatic castration-resistant prostate cancer (CRPC).\n   20. Adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology.\n   21. Surgically or medically castrated, with testosterone levels of \\\u003C50 ng\u002FdL.\n   22. Documented objective progression as determined by radiographic progression for subjects with measurable disease after androgen deprivation.\n   23. Relapsed or disease progression after having received treatment with ≥1 of the following novel hormonal agents: abiraterone, enzalutamide, apalutamide, or darolutamide.\n   24. Relapsed or disease progression after having received ≥1 cytotoxic chemotherapy regimen that included a taxane.\n\n       Gastric Cancer 2L\n   25. Must have had gastric or GEJ adenocarcinoma confirmed as negative for HER2 expression (IHC 0\u002F1+ or IHC 2+\u002Fin situ hybridization negative) as classified by American Society of Clinical Oncology\u002FCollege of American Pathologists (ASCO-CAP) guidelines and determined prior to enrollment by assessment in a local laboratory that is Clinical Laboratory Improvement Amendments certified (US sites) or accredited based on specific country regulations.\n   26. Disease progression after having received treatment with only 1 prior line of systemic anti-cancer therapy that includes 5-FU-based chemotherapy with or without an anti-PD-1 therapy. For subjects whose tumors are claudin (CLDN) 18.2 positive, treatment with 5-FU based chemotherapy with CLDN18.2 directed therapy in the first-line setting is allowed.\n\n   Non-small Cell Lung Cancer aa. Histologically or cytologically documented metastatic or locally advanced nonsquamous NSCLC not amenable to curative surgery or radiation bb. Documentation of absence of actionable driver mutation (ie, ALK rearrangement, BRAF V600E mutation, EGFR-activating mutations \\[exon 19 deletion or L858R mutation\\], EGFR exon 20 insertion mutation, HER2 mutation, KRAS G12C mutation, MET exon 14 skipping mutation, NTRK 1\u002F2\u002F3 gene fusion, RET rearrangement, or ROS1 rearrangement). New testing for these genomic alterations is not required for Screening.\n\n   cc. Relapsed or disease progression after receiving only anti-PD-(L)1 and PBC (ie, platinum doublet) administered in combination or sequentially for metastatic disease.\n\n   Breast Cancer dd. Pathologically documented breast cancer that is assessed as HER2 negative (IHC2+\u002FISH-, IHC1+, or IHC0 per ASCO\u002FCAP guidelines), and HR positive (either ER and\u002For PgR positive \\[ER or PgR ≥1%\\] per ASCO\u002FCAP guidelines). The HER2 and HR results must be from a tumor sample obtained in the metastatic setting.\n\n   ee. Participant must have received one line of chemotherapy for mBC, but not more than one line and must have a clinically or radiologically documented evidence of tumor progression on or after CDK 4\u002F6 inhibitor combined with endocrine therapy; previous treatments with phosphoinositide 3-kinase (PI3K) inhibitors, mammalian target of rapamycin (mTOR) inhibitors, protein kinase B (PKB) inhibitors also known as AKT-inhibitors and poly ADP ribose polymerase (PARP)-inhibitors are allowed.\n4. Has ≥1 measurable lesion on CT or MRI as per RECIST v1.1 by investigator assessment. Prostate cancer participants with bone only disease may be eligible.\n5. Provides a pretreatment tumor tissue sample that meets 1 of the following collection requirements:\n\n   1. Tumor biopsy from ≥1 lesion not previously irradiated and performed since progression with the most recent systemic cancer therapy regimen and prior to signature of the tissue ICF (ARCHIVAL PRETREATMENT sample).\n\n      OR\n   2. Newly obtained pretreatment tumor biopsy from ≥1 lesion not previously irradiated and amenable to sampling, after signature of tissue ICF (FRESH PRETREATMENT sample)\n6. Has Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 at screening.\n\nExclusion Criteria\n\nParticipants who meet any of the following criteria will be disqualified from entering the study:\n\n1. Has HER2-positive gastric cancer as classified by ASCO-CAP guidelines and determined prior to enrollment by assessment in a local laboratory that is Clinical Laboratory Improvement Amendments certified (US sites) or accredited based on specific country regulations.\n2. Has nasopharyngeal cancer.\n3. Has mucosal or uveal melanoma.\n4. Has a history of (non-infectious) interstitial lung disease (ILD), that required corticosteroids, has current ILD\u002Fpneumonitis, or suspected ILD\u002Fpneumonitis cannot be ruled out by imaging at screening.\n5. Has clinically severe respiratory compromise (based on the investigator's assessment) resulting from intercurrent pulmonary illnesses\n6. Is receiving chronic systemic corticosteroids dosed at \\>10 mg prednisone daily or equivalent anti-inflammatory activity or any form of immunosuppressive therapy prior to Cycle 1 Day 1.\n\n   Participants who require use of bronchodilators, inhaled or topical steroids, or local steroid injections may be included in the study.\n7. Had prior treatment with an anti-HER3 antibody and\u002For antibody-drug conjugate (ADC) that consists of an exatecan derivative that is a topoisomerase I inhibitor (eg, trastuzumab deruxtecan).\n8. Has history of other active malignancy within 3 years prior to Cycle 1 Day 1, except the following:\n\n   1. Adequately treated nonmelanoma skin cancer\n   2. Adequately treated intraepithelial carcinoma of the cervix\n   3. Any other curatively treated in situ disease\n9. Has any evidence of severe or uncontrolled diseases (eg, active bleeding diatheses, active serious infection) psychiatric illness\u002Fsocial situations, geographical factors, substance abuse, or other factors that, in the investigator's opinion, make it high risk for the subject to participate in the study or that would jeopardize compliance with the protocol\n10. Has previously received topoisomerase-1 inhibitors (e.g., irinotecan) treatment in the advanced or metastatic disease setting.",{"count":123,"type":21},740,[125],"PHASE2","This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \\[cutaneous\u002Facral\\], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric cancer ovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, prostate cancer, second-line gastric cancer, lung cancer, and breast cancer.",[128,27,32,129,130,67,70,68,131,132,71,133,26,25],"Advanced Solid Tumor","Gastric Cancer","Ovarian Carcinoma","Esophageal Cancer","Pancreatic Carcinoma","Non-small Cell Lung Cancer (NSCLC)",[128,27,32,129,135,136,137,138,139,140,141,142,143,144,26,25],"Ovarian carcinoma","Cervical cancer","Endometrial cancer","Bladder cancer","Esophageal carcinoma","Pancreatic carcinoma","Prostate cancer","Patritumab Deruxtecan","HER3-DXd","U3-1402",{"date":42,"type":43},{"date":147,"type":43},"2024-02-26",{"date":149,"type":21},"2028-10-10",{"name":151,"class":152},"Daiichi Sankyo","INDUSTRY",86,{"id":155,"slug":156,"hasResults":12,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":163,"conditions":164,"keywords":167,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":182},"100652599","pd-l1-inhibitor-rechallenge-after-immunotherapy-related-pneumonitis-in-patients-with-lung-cancer-100652599","NCT07775820","PD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung Cancer","Efficacy and Safety of PD-L1 Inhibitor Rechallenge After Immune Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer: A Multicenter Real-World Study","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Histologically confirmed lung cancer.\n3. Development of checkpoint inhibitor pneumonitis after treatment with immune checkpoint inhibitor.\n4. Eastern Cooperative Oncology Group performance status of 0, 1, or 2.\n5. Provision of written informed consent.\n\nExclusion Criteria:\n\n1. Incomplete clinical information required for the study analyses.\n2. Considered unsuitable for participation by the investigator.",{"count":162,"type":21},150,"This multicenter observational study will evaluate the safety and effectiveness of immune checkpoint inhibitor rechallenge in adults with lung cancer who developed checkpoint inhibitor pneumonitis.\n\nThe study will use both retrospective medical records and prospective follow-up data. Participants will not be assigned to any treatment by the study protocol. All treatment decisions will be made by the treating physicians as part of routine clinical care.\n\nParticipants will be classified into three groups according to their subsequent treatment: rechallenge with a PD-L1 inhibitor, rechallenge with a PD-1 inhibitor, or no immune checkpoint inhibitor rechallenge. The primary outcome is the recurrence of checkpoint inhibitor pneumonitis after rechallenge. Secondary outcomes include immune-related adverse events, progression-free survival, overall survival, objective response rate, and disease control rate at 24 weeks.\n\nApproximately 150 participants will be included across multiple study centers in China.",[26,165,166],"Rechallenge","Checkpoint Inhibitor Pneumonitis",[168,169,170,171,166,172,173],"Immune Checkpoint Inhibitor","PD-L1 Inhibitor","PD-1 Inhibitor","Immune Checkpoint Inhibitor Rechallenge","Immune-Related Adverse Events","Real-World Study","2026-08-18",{"date":80,"type":43},{"date":177,"type":43},"2025-10-20",{"date":179,"type":21},"2027-06-30",{"name":181,"class":50},"Nanfang Hospital, Southern Medical University",5,{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":190,"enrollmentInfo":191,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":193,"conditions":194,"keywords":195,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":198,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":205},"100125189","collecting-and-analyzing-tissue-samples-from-patients-undergoing-surgery-for-non-small-cell-lung-cancer-100125189","NCT00897117","Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer","Molecular Fingerprinting of Lung Cancer","Inclusion criteria\n\n* Diagnosis of non-small cell lung cancer\n\n  * Clinical stage I and II disease\n  * Resectable disease and complete surgical resection planned\n* Treated on companion studies at Vanderbilt University, the Veterans Administration hospital, St. Thomas, and Vanderbilt-Ingram Cancer Center Affiliate Network\n* Tumor specimen samples must be available at resection\n\nExclusion criteria\n\n* Chemotherapy before surgery\n* Radiotherapy before surgery","120 Years",{"count":192,"type":21},4000,"RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that may occur in RNA and identify biomarkers related to cancer.\n\nPURPOSE: This research study is collecting and analyzing lung tissue samples from patients undergoing surgery for non-small cell lung cancer.",[26],[196,197],"stage I non-small cell lung cancer","stage II non-small cell lung cancer",{"date":80,"type":43},{"date":200,"type":43},"2001-05-01",{"date":202,"type":21},"2031-05-31",{"name":204,"class":50},"Vanderbilt-Ingram Cancer Center",3,{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":62,"phases":216,"briefSummary":218,"conditions":219,"keywords":221,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":225,"completionDateStruct":226,"leadSponsor":228,"locationsCount":230},"100631361","phase-3-evaluation-of-the-safety-and-efficacy-of-abenacianine-vgt-309-to-identify-cancer-in-subjects-undergoing-surgery-for-cancer-in-the-lung-100631361","NCT07499674","Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung","A Phase 3, Multi-center, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Abenacianine (VGT-309), a Tumor-Targeted, Activatable Fluorescent Imaging Agent, to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung - VISUALIZE 2","VISUALIZE-2","Inclusion Criteria:\n\n1. Be willing and able to sign the informed consent and comply with study procedures.\n2. Be at least 18 years of age.\n3. Be scheduled for or planning to have a surgical resection of a lung lesion or mass with diagnostic and\u002For curative intent.\n4. Meet all requirements for the planned surgery based on opinion of the surgeon, anesthesiologist, and\u002For other consulting physician.\n5. Be able to meet the following conditions:\n\n   1. Female participants must be of non-childbearing potential, or,\n   2. If of childbearing potential, be non-pregnant or non-lactating and agree to use highly effective contraception from screening through Day 30 after treatment.\n   3. Male participants, if not surgically sterilized, and if engaging in sexual intercourse with a female partner of childbearing potential, must be willing to use highly effective contraception from screening through 30 days after dosing.\n6. Have not participated in an interventional clinical trial within the last 30 days.\n\nExclusion Criteria:\n\n1. They have a known allergy or reaction to radiographic contrast agents, ICG, or any component of abenacianine.\n2. They have received chemotherapy, immunotherapy or radiotherapy within 4 weeks prior to study enrollment.\n3. They have any other co-morbidity or habit that the Investigator believes will interfere with their ability to comply with and complete the study. They are not a candidate for standard of care surgery based on opinion of the surgeon, anesthesiologist, or other consulting physician.\n4. They are prisoners, institutionalized individuals, or are unable to consent for themselves.",{"count":215,"type":21},132,[217],"PHASE3","This is a Phase 3, multi-center, randomized and intrasubject controlled study to evaluate the safety and efficacy of abenacianine for injection, a tumor-targeted, activatable fluorescent imaging agent, to identify cancer using NIR imaging in participants undergoing surgery for cancer in the lung. Approximately 132 partiipants will be enrolled to ensure a minimum of 115 evaluable participants receiving abenacianine and undergoing NIR imaging and a control group of 12 participants who will receive abenacianine but no NIR imaging.",[26,220],"Lung Metastases",[26,222],"Metastatic Cancer in Lung","2026-08-17",{"date":40,"type":43},{"date":45,"type":43},{"date":227,"type":21},"2027-03",{"name":229,"class":152},"Vergent Bioscience, Inc.",9,{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":62,"phases":240,"briefSummary":242,"conditions":243,"keywords":244,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":249,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":256},"100563601","phase-1-a-study-to-evaluate-the-safety-tolerability-drug-levels-and-preliminary-efficacy-of-bms-986507-combinations-in-adult-participants-with-advanced-solid-tumors-100563601","NCT06618287","A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors","A Phase 1\u002F2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors","Inclusion Criteria\n\n* Participants must have at least one measurable lesion per response evaluation criteria in solid tumors.\n* Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n* Participants must have a life expectancy of at least 3 months at the time of the first dose.\n* Group A: Participants must have pathologically confirmed locally advanced or metastatic NSCLC with an EGFR exon 19 deletion or L858R mutation in exon 21, either alone or in combination with other EGFR mutations, which may include T790M in exon 20. Participants with other EGFR mutations (including but not limited to, exon 21 L861Q, exon 18 G719X, and exon 20 S768I mutations, etc.) will also be allowed\n* Group B: Participants must have pathologically confirmed locally advanced or metastatic NSCLC.\n* Group C: Participants must have pathologically confirmed locally-advanced, recurrent inoperable, or metastatic TNBC or ER-low, HER2-negative BC.\n* Group D: Participants must have pathologically confirmed locally-advanced, recurrent inoperable, or metastatic TNBC per ASCO\u002FCAP criteria, based on the most recently analyzed biopsy or another pathology specimen.\n* Group E: Participants must have pathologically confirmed locally advanced or metastatic NSCLC, not amenable to treatment in curative intent.\n\nExclusion Criteria\n\n* Participants must not have any mixed Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) histology.\n* Participants with known mutations in EGFR will be excluded (Group A,B and E).\n* Participants must not have a history of serious recurrent infections.\n* Participants must not have a history of severe heart disease.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",{"count":239,"type":21},416,[241,125],"PHASE1","The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.",[26,25],[245,246,247,248],"Non-Small Cell Lung Cancer (NSCLC)","Epidermal Growth Factor Receptor mutated (EGFRmt)","Epidermal Growth Factor Receptor wild-type (EGFRwt)","Triple-negative breast cancer (TNBC)",{"date":174,"type":43},{"date":251,"type":43},"2025-02-04",{"date":253,"type":21},"2031-02-26",{"name":255,"class":152},"Bristol-Myers Squibb",66,{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":17,"minAge":264,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":62,"phases":267,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":271,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":51},"100499790","home-based-respiratory-muscle-training-for-minimizing-side-effects-in-patients-undergoing-treatment-for-cancer-100499790","NCT05787834","Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for Cancer","Respiratory Muscle Training During Cancer Treatment: Effects on the Autonomic Nervous System and Cardiotoxicity","Inclusion Criteria:\n\n* Able and willing to provide written informed consent\n* Age \\>= 21 years old\n* Diagnosed with solid tumor (e.g., head and neck, thoracic, or breast cancer)\n* Scheduled to receive at least one dose of chemotherapy or immunotherapy or radiation\n* Treated at Roswell Park Comprehensive Cancer Center\n\nExclusion Criteria:\n\n* Presence of oral mucosal disease including oral mucositis, or oral candidiasis detected at baseline\n* Have uncontrolled intercurrent illness including, but not limited to, ongoing or active respiratory infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, heart failure or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study intervention","21 Years",{"count":266,"type":21},130,[64],"This clinical trial evaluates whether home-based respiratory muscle training is useful for minimizing side effects in patients undergoing treatment for cancer. Over-activation of the nervous system during breast cancer treatment can result in heart- and lung-related side effects which have the potential to reduce a patient's quality of life. Aerobic exercise can help prevent the development of these side effects. However, engaging in regular aerobic exercise may be difficult for breast cancer patients who are actively undergoing treatment. Respiratory muscle training (RMT) involves a series of breathing and other exercises that are performed to improve the function of the respiratory muscles through resistance and endurance training. Home-based RMT may represent a more feasible approach for reducing side effects in patients undergoing treatment for breast cancer.",[270,32,26],"Breast Carcinoma",{"date":40,"type":43},{"date":273,"type":43},"2023-10-16",{"date":275,"type":21},"2029-10-16",{"name":277,"class":50},"Roswell Park Cancer Institute",{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":12,"sex":285,"minAge":4,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":288,"conditions":289,"keywords":290,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":51},"100602341","demographics-of-lung-cancer-in-females-100602341","NCT07122245","Demographics of Lung Cancer in Females","Demographics of Lung Cancer in Female Patients: A Retrospective Based Analysis","Inclusion Criteria:\n\n* All female patients presented with bronchogenic carcinoma patients and diagnosed at chest diseases department, Oncology Center Mansoura University (OCMU) in last 10 years.\n\nExclusion Criteria:\n\n* lung metastasis ( not primary bronchogenic carcinoma)","FEMALE",{"count":287,"type":21},300,"Lung cancer has been the most common and fatal type of cancer; indeed worldwide incidence of lung cancer is alarming. It is considered a leading cause of cancer- related deaths among males and females due to environmental pollution, occupational exposure, genetic susceptibility, increasing number of smokers and others.",[26],[291,292,293],"Demographics","lung cancer","female patients","2026-08-16",{"date":174,"type":43},{"date":297,"type":43},"2025-08-07",{"date":299,"type":21},"2027-04-07",{"name":301,"class":50},"Mansoura University Hospital",{"id":303,"slug":304,"hasResults":12,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":17,"minAge":309,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":312,"conditions":313,"keywords":316,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":326,"completionDateStruct":4,"leadSponsor":328,"locationsCount":51},"100166536","collection-of-blood-from-patients-with-cancer-other-tumors-or-tumor-predisposition-syndromes-for-genetic-analysis-100166536","NCT01441089","Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis","Collection of Blood From Therapeutic Trial Participants for Analysis of Genetic Differences in Drug Disposition and Pharmacokinetics of Probe Medications","* INCLUSION CRITERIA:\n* Any individual currently enrolled in an NIH intramural research program clinical trials receiving treatment.\n* Ability of participant or Legally Authorized Representative (LAR) to understand and be willing to sign the informed consent document.\n* Age \\>= 3 years old\n\nEXCLUSION CRITERIA:\n\n-N\u002FA","3 Years",{"count":311,"type":21},1100,"Background:\n\n\\- Some genes may be associated with a greater chance of side effects during cancer treatment. These genes may also make certain treatments less effective. Researchers want to collect blood or cheek swab samples from people having cancer treatment to study these genes.\n\nObjectives:\n\n\\- To obtain a blood or cheek swab sample to study genetic differences that may affect cancer treatment.\n\nEligibility:\n\n\\- Individuals with cancer who are being treated at the National Cancer Institute.\n\nDesign:\n\n* Participants will provide a blood sample for study.\n* Participants who have blood-based cancer, such as leukemia, will provide a cheek swab sample.\n* If the blood or cheek swab sample does not have enough genetic material for analysis, an additional sample may be collected.",[71,25,26,314,315],"Ovarian Cancer","Lymphoma",[317,318,319,320,321,322,323],"Pharmacogenetics","Pharmacokinetics","Pharmacodynamics","Clinical Outcome","Drug Metabolism and Transport","Natural History","Cancer","2026-08-15",{"date":174,"type":43},{"date":327,"type":43},"2012-05-21",{"name":329,"class":330},"National Cancer Institute (NCI)","NIH",{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":337,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":338,"conditions":339,"keywords":341,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":345,"startDateStruct":346,"completionDateStruct":4,"leadSponsor":348,"locationsCount":51},"100054764","evaluation-for-nci-surgery-branch-clinical-research-protocols-100054764","NCT00001823","Evaluation for NCI Surgery Branch Clinical Research Protocols","* INCLUSION CRITERIA:\n\nAge \\>= 18 years.\n\nPatient suspected of having, or with biopsy proven, malignant disease.\n\nPatient is able to understand and willing to sign a written informed consent document.\n\nPatient is being evaluated for treatment on an NCI-SB protocols.\n\nEXCLUSION CRITERIA:\n\nWomen of child-bearing potential who are pregnant or plan to become pregnant because of the potentially dangerous effects of some of the screening procedures (e.g., nuclear medicine or other imaging scans) on the fetus.",{"count":20,"type":21},"Background:\n\nThe National Cancer Institute Surgery Branch (NCI-SB) has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient.\n\nObjective:\n\nThis study will allow patients to under screening and evaluation for participation in NC-SB Protocols.\n\nEligibility:\n\nPatients 18 years or older must meet the minimum eligibility criteria for an NCI-SB treatment protocol.\n\nDesign\n\nPatients will undergo testing and evaluations as required by the appropriate NCI-SB treatment protocol.\n\n...",[340,27,69,26,68],"Synovial Cell Cancer",[323,342,343,344],"Gene Therapy","Immunotherapy","Clinical Trial",{"date":174,"type":43},{"date":347,"type":43},"1999-07-11",{"name":329,"class":330},{"id":350,"slug":351,"hasResults":12,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":355,"eligibilityCriteria":356,"healthyVolunteers":94,"sex":17,"minAge":95,"maxAge":96,"enrollmentInfo":357,"targetDuration":4,"studyType":62,"phases":359,"briefSummary":360,"conditions":361,"keywords":363,"overallStatus":370,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":51},"100651832","feasibility-and-uptake-of-low-dose-ct-lung-cancer-screening-in-kuwait-100651832","NCT07766538","Feasibility and Uptake of Low-Dose CT Lung Cancer Screening in Kuwait","ALIA Kuwait: A Prospective Pilot Feasibility Study of Low-Dose Computed Tomography Screening for Lung Cancer in High-Risk Individuals in Kuwait","ALIA","Inclusion Criteria:\n\n* Age 50 to 80 years\n* Smoking history of at least 20 pack-years, totalled across all tobacco products using pre-specified equivalency conventions (1 shisha head-year = 1 pack-year; 1 cigar = 4 cigarettes; 1 pipe bowl = 2.5 cigarettes; roll-your-own tobacco 1 g = 1 cigarette). Current and former smokers are eligible regardless of time since quitting.\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Previous diagnosis of lung cancer\n* Currently under surveillance for pulmonary nodules\n* Currently undergoing diagnostic assessment, treatment, or surveillance for major comorbidities\n* Unable to lie flat with arms raised above the head for CT scanning\n* Symptoms suggestive of lung cancer (persistent or worsening cough, haemoptysis, or unexplained weight loss of more than 7 kg in the past year)",{"count":358,"type":21},500,[64],"Lung cancer is a leading cause of cancer-related death in Kuwait, where most cases are diagnosed at an advanced stage and there is no national screening program. This prospective pilot feasibility study will offer low-dose computed tomography (LDCT) screening to approximately 500 high-risk individuals aged 50-80 years across Kuwait. The primary objective is to assess the uptake of, and barriers to, LDCT lung cancer screening in Kuwait and to establish a framework for a national screening program. Participants undergo eligibility assessment (smoking history of at least 20 pack-years, totalled across all tobacco products using pre-specified equivalency conversions for shisha\u002Fwaterpipe, cigar, pipe, and roll-your-own tobacco), baseline assessment, LDCT screening with Lung-RADS-based management, a second screening round at 12 months, and follow-up. LDCT images are read by radiologists and in parallel by artificial intelligence (AI) software to evaluate AI-assisted reading. Findings will inform national lung cancer screening guidelines for Kuwait.",[26,362],"Lung Neoplasms",[104,364,365,366,367,368,369],"low-dose computed tomography","Lung-RADS","artificial intelligence","shisha waterpipe smoking","Kuwait","pilot feasibility study","NOT_YET_RECRUITING","2026-08-14",{"date":223,"type":43},{"date":374,"type":21},"2026-09-01",{"date":376,"type":21},"2029-08-31",{"name":378,"class":379},"Sulaiman Khadadah","OTHER_GOV",{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":387,"targetDuration":4,"studyType":62,"phases":389,"briefSummary":390,"conditions":391,"keywords":397,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":402,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":409},"100610052","phase-3-symbiotic-lung-01--a-study-to-learn-about-the-study-medicine-called-pf-08634404-in-combination-with-chemotherapy-in-adult-participants-with-locally-advanced-or-metastatic-non-small-cell-lung-cancer-100610052","NCT07222566","Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER","Inclusion Criteria:\n\n* 18 years of age or older at screening.\n* Have pathologically confirmed locally advanced (Stage IIIB\u002FIIIC) or metastatic (Stage IV)squamous or non-squamous NSCLC and not be a candidate for complete surgical resection and curative concurrent\u002Fsequential chemoradiotherapy (according to the 9th edition of the Union for International Cancer Control and American Joint Committee on Cancer lung cancer Tumor, lymph nodes, metastasis (TNM) staging system).\n* Have tumor tissue available, either paraffin block or slides from a core, excisional or fine needle biopsy\n* PD-L1 status available based on local testing results\n* Measurable disease based on RECIST v1.1 per investigator.\n* Eastern Cooperative Oncology Group performance status (ECOG) score of 0 or 1\n* Expected survival ≥12 weeks\n\nExclusion Criteria:\n\n* Participants with known actionable genomic alteration (AGAs), including estimated glomerular filtration rate (EGFR), anaplastic lymphoma kinase (ALK), Repressor of Silencing 1 (ROS1), neurotrophic tyrosine receptor kinase (NTRK), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), rearranged during transfection (RET), and mesenchymal-epithelial transition (MET), for which there are available first-line therapies per local standard-of-care (SOC) are ineligible. Documented negative results for EGFR, ALK, and ROS1 AGAs are required for participants with non-squamous histology.\n* Known active CNS lesions are excluded. Participants with definitively treated brain metastases (surgery and\u002For radiotherapy) may be eligible. Clinically inactive brain metastases of longest diameter \\\u003C 1 cm are permitted.\n* Participants with clinically significant risk of hemorrhage or fistula are excluded.\n* Participants with any history of another malignancy within 3 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy.\n* Unresolved toxicities from prior anti-tumor therapy, that did not recover to NCI CTCAE v5.0 Grade 0 or 1.\n* Known to have a history of a severe allergy to any component of the study intervention, or a history of severe allergic reaction to chimeric or humanized antibody.\n* History of allogeneic organ \u002F hematopoietic stem cell transplantation.\n* Participants with any of the following respiratory conditions:\n* Evidence of noninfectious or drug-induced interstitial lung disease (ILD) or pneumonitis\n* Grade ≥3 pulmonary disease unrelated to underlying malignancy\n* History of uncontrolled comorbidities within 6 months prior to the first dose including uncontrolled cardiac and cerebrovascular conditions, hypertension, diabetes, significant vascular disease or arterial\u002Fsevere venous thromboembolic events.\n* Major surgery \\\u003C 4 weeks or minor surgery \\\u003C 3 days prior to first dose of study intervention.\n* History of severe bleeding tendency or coagulation dysfunction\n* History of esophageal varices, severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding within 6 months prior to the first dose.\n* Participants with acute, chronic or symptomatic infections including participants positive for active HIV, hepatitis B virus (HBV), or Hepatitis C virus (HCV).\n* Participants with history of immunodeficiency\n* Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation\u002Fbehavior (in the past 5 years) or laboratory abnormality that may increase the risk of study participation or make the participant inappropriate for the study.\n* Previous systemic anti-tumor therapy including:\n\n  1. Prior systemic therapy, including anti-PD-(L)1 therapy, for locally advanced, unresectable, or metastatic NSCLC.\n  2. Previous treatment with immunotherapy\n  3. Prior radiotherapy \\> 30 Gy to the lung \\\u003C 6 months of first dose of study intervention\n  4. Palliative local therapy \\\u003C 2 weeks before the first dose of study intervention;\n  5. Non-specific immunomodulatory therapy \\\u003C 2 weeks before the first dose.\n  6. Prior systemic anti-angiogenic therapy\n* Prior immune-related AE that led to anti-PD-(L)1 treatment discontinuation, adverse events from prior immunotherapy not improved to Grade 1 before screening, or required treatment with systemic immunosuppressive therapy.\n* Prior and concomitant therapy:\n\n  1. therapeutic oral or parenteral anticoagulants or thrombolytic agents \\\u003C 10 days to the first dose.\n  2. chronic antiplatelet therapy \\\u003C7 days to randomization.\n  3. live or attenuated live vaccine \\\u003C 4 weeks to the first dose.\n  4. current high-dose systemic corticosteroids.\n  5. prohibited concomitant medication(s) \\\u003C 21 days to the first dose.\n* Breastfeeding participants, participants of childbearing potential, and male participants who are unwilling to follow contraceptive measures.",{"count":388,"type":21},1410,[217],"This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that is either locally advanced (spread to nearby tissues) or has spread to other parts of the body.\n\nTo join the study, participants must meet the following conditions:\n\n* Be 18 years or older.\n* Have locally advanced (Stage IIIB\u002FIIIC) or metastatic (Stage IV) squamous or non-squamous NSCLC.\n* Is not a candidate for complete surgical resection or curative chemoradiotherapy.\n* Do not have known actionable genomic alterations\n* Be treatment naïve for advanced or metastatic disease\n\nParticipants in this study will be assigned to two different parts of the study depending on their type of tumor: participants with squamous NSCLC will be assigned to Part 1, while participants with non-squamous NSCLC will be assigned to Part 2.\n\nEach participant will be randomly assigned (like a flip of the coin) to one of two treatment groups in a blinded fashion:\n\n* Part 1 - Arm A or Part 2 - Arm C (Experimental Group): Will receive a new study medicine called PF-08634404 along with a kind of chemotherapy specific to the type of tumor.\n* Part 1 - Arm B or Part 2 - Arm D (Control Group): Will receive an approved medicine called pembrolizumab along with a kind of chemotherapy specific to the type of tumor.\n\nParticipants will receive their assigned treatment through intravenous (IV) infusions, which means the medicine is given directly into a vein. The treatment will be given in cycles, participants will receive PF-08634404 or Pembrolizumab in combination with chemotherapy followed by maintenance with either PF-08634404 or Pembrolizumab monotherapy (Part 1) or PF-08634404 or Pembrolizumab in combination with a chemotherapeutic drug (Part 2). Participants will continue receiving treatment if it is helping and not experiencing serious side effects.\n\nThe study will include regular visits for:\n\n* Treatment and health checks: while participant continues receiving treatment.\n* Tests to monitor how cancer responds: every 6 weeks during the first 48 weeks, then every 12 weeks thereafter.",[392,393,394,395,396,26],"Advanced Non-Small Cell Lung Cancer","Non-Small Cell Lung Cancer","Carcinoma, Non-Small-Cell Lung","Carcinoma, Non-Small-Cell Lung (NSCLC)","Metastatic Non Small Cell Lung Cancer",[398,399,400,401],"non-squamous NSCLC","squamous NSCLC","metastatic (Stage IV) squamous or non-squamous NSCLC","Advanced or Metastatic Non-Small Cell Lung Cancer",{"date":223,"type":43},{"date":404,"type":43},"2026-01-06",{"date":406,"type":21},"2032-08-26",{"name":408,"class":152},"Pfizer",440,{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":417,"targetDuration":4,"studyType":62,"phases":419,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":424,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":431},"100579303","phase-2-a-single-arm-phase-2-study-of-datopotamab-deruxtecan-carboplatin-and-pembrolizumab-for-treatment-naive-brain-metastases-from-nsclc-non-small-cell-lung-cancer-100579303","NCT06822543","A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)","TROPICAL-1","Inclusion Criteria:\n\n\\- Male\u002Ffemale participants who are at least 18 years of age on the day of signing informed consent with a histologically confirmed diagnosis of NSCLC will be enrolled in this study.\n\nHistologically confirmed metastatic non-squamous NSCLC with PD-L1 tumor proportion score \\\u003C50% determined by local or central laboratory using antibodies 22C3'\n\n* Documented negative test results for EGFR and ALK actionable genomic alterations by local test;\n* No known actionable genomic alterations in ROS1, NTRK, RET, HER2, or MET.\n* No prior systemic therapy for advanced or metastatic NSCLC. Patients who received chemotherapy or immunotherapy for localized or locally advanced NSCLC are eligible if progression occurred at least 6 months after the last dose of systemic treatment.\n* Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement or participants who have ≤Grade 2 neuropathy are eligible.\n* The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.\n* Have measurable disease based on RECIST 1.1, including the following:\n\nPresence of 1 or more measurable central nervous system (CNS) metastases that have not received prior radiation therapy, or presence of 1 or more measurable central nervous system (CNS) metastases that has received prior radiation therapy but has unequivocally progressed within the radiation therapy field; Measurable brain metastasis is defined as any lesion that can be accurately measured in at least one dimension as ≥ 10mm. Patients with brain metastases lesions ≥ 5 mm and \\\u003C 10 mm are considered to have measurable disease and are allowed to be enrolled if MRI slice thickness is 1.5 mm or less.\n\nPresence of 1 or more measurable extracranial lesion; Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.\n\n\\- No neurological symptoms that require immediate and significant intervention, in the opinion of the treating physician. Patients with neurologic symptoms that do not require significant medical intervention are allowed. Patients may also be enrolled after control of neurological symptoms that require immediate and significant intervention.\n\nPatients with neurologic symptoms that are controlled with anticonvulsants are allowed.\n\nPatients with neurologic symptoms that are controlled with stable (for at least 1 week), low dose dexamethasone (≤4 mg daily) are allowed.\n\n* No leptomeningeal carcinomatosis.\n* Archival tumor tissue sample or newly obtained \\[core, incisional or excisional\\] biopsy of a tumor lesion has been provided. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slide (preferably a minimum of 20 slides).\n\nHave an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Evaluation of ECOG is to be performed within 7 days prior to the first dose of study intervention.\n\nLife expectancy of \\> 12 weeks.\n\nHas had an adequate treatment washout period before Cycle 1 Day 1, defined as:\n\nMajor surgery: ≥ 3 weeks. Chloroquine\u002Fhydroxychloroquine: \\> 14 days.\n\n\\- Participants who are HBsAg positive are eligible if they have received HBV anti-viral therapy for at least 4 weeks and have undetectable HBV viral load prior to inclusion.\n\nNote: Participants should remain on anti-viral therapy throughout study intervention and follow local guidelines for HBV anti-viral therapy post completion of study intervention.\n\n\\- Hepatitis B screening tests are not required unless: Known history of HBV infection. As mandated by local health authority. Participants with a history of HCV infection are eligible if HCV viral load is undetectable at screening.\n\n\\- Note: Participants must have completed curative anti-viral therapy at least 4 weeks prior to inclusion.\n\nHepatitis C screening tests are not required unless:\n\nKnown history of HCV infection As mandated by local health authority\n\n\\- HIV-infected participants must have well-controlled HIV on ART, defined as: Participants on ART must have a CD4+ T-cell count ≥350 cells\u002Fmm3 at the time of screening Participants on ART must have achieved and maintained virologic suppression defined as confirmed HIV RNA level below 50 or the LLOQ (below the limit of detection) using the locally available assay at the time of screening and for at least 12 weeks before screening.\n\n\\- It is advised that participants must not have had any AIDS-defining opportunistic infections within the past 12 months.\n\nParticipants on ART must have been on a stable regimen, without changes in drugs or dose modification, for at least 4 weeks before study entry (Day 1) and agree to continue ART throughout the study The combination ART regimen must not contain any antiretroviral medications that interact with CYP3A4 inhibitors\u002Finducers\u002Fsubstrates (https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-interactions-labeling\u002Fdrug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers)\n\n* Negative pregnancy test (serum) for women of childbearing potential.\n* Have adequate organ function. Specimens must be collected within 10 days prior to the start of study intervention.\n* Hematological: Absolute neutrophil count (ANC) ≥1500\u002FµL; Platelets ≥100 000\u002FµL; Hemoglobin\n\n  ≥9.0 g\u002FdL or ≥5.6 mmol\u002FLa;\n* Renal: Creatinine OR Measured or calculatedb creatinine clearance (GFR can also be used in place of creatinine or CrCl) ≤1.5 × ULN OR ≥30 mL\u002Fmin for participant with creatinine levels \\>1.5 × institutional ULN\n* Hepatic: Total bilirubin ≤1.5 ×ULN OR direct bilirubin ≤ULN for participants with total bilirubin levels \\>1.5 × ULN AST (SGOT) and ALT (SGPT) ≤2.5 × ULN (≤5 × ULN for participants with liver metastases)\n* Coagulation: International normalized ratio (INR) OR prothrombin time (PT) Activated partial thromboplastin time (aPTT) ≤1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants;\n* ALT (SGPT)=alanine aminotransferase (serum glutamic pyruvic transaminase); AST (SGOT)=aspartate aminotransferase (serum glutamic oxaloacetic transaminase); GFR=glomerular filtration rate; ULN=upper limit of normal.\n\n  1. Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within the last 2 weeks.\n  2. Creatinine clearance (CrCl) should be calculated per institutional standard.\n\nExclusion Criteria:\n\n* Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to inclusion.\n* Has received prior radiotherapy to the brain within 2 weeks of the start of therapy, or received radiotherapy to the chest within 4 weeks of start of therapy, or that have ongoing radiation-related toxicities requiring corticosteroid.\n* Has received a live vaccine or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.\n* Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration.\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug. Use of dexamethasone ≤ 4 mg\u002Fday (or another steroid at equivalent doses) is allowed for treatment of neurological symptoms.\n* Has spinal cord compression.\n* Uncontrolled or significant cardiovascular disease, including: Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) interval \\>470 msec regardless of sex; Myocardial infarction within 6 months prior to inclusion; Uncontrolled angina pectoris within 6 months prior to inclusion; Known LVEF \\\u003C50% by ECHO or MUGA scan within 28 days before inclusion; New York Heart Association Class 2 to 4 congestive heart failure (CHF) at screening; Uncontrolled hypertension within 7 days before inclusion.\n* Known additional malignancy that is progressing or has required active treatment within the past 5 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ, excluding carcinoma in situ of the bladder, which have undergone potentially curative therapy are not excluded. Participants with low-risk early-stage prostate cancer (T1-T2a, Gleason score ≤6, and PSA \\\u003C10 ng\u002FmL) either treated with definitive intent or untreated in active surveillance with stable disease are not excluded.\n* Has severe hypersensitivity (≥Grade 3) to either pembrolizumab and\u002For any of its excipients and\u002For Dato-DXd including its excipients (e.g. polysorbate 80).\n* Has a history of non-infectious ILD\u002Fpneumonitis including radiation pneumonitis that required steroids, has current ILD\u002Fpneumonitis, or has suspected ILD\u002Fpneumonitis that cannot be ruled out by imaging at screening.\n* Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses (including pulmonary embolism within 3 months of enrollment, severe asthma, severe oxygen-dependent chronic obstructive pulmonary disease, restrictive lung disease, pleural effusion) or autoimmune disease with lung involvement (i.e. rheumatoid arthritis, Sjogren disease, sarcoidosis, etc) with pulmonary involvement documented or suspected at screening.\n* Clinically significant known corneal disease.\n* Known active tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice).\n* Severe infection within 4 weeks prior to the first dose of study treatment (Cycle 1, Day 1), including but not limited to hospitalization for complications of infection, bacteraemia, or severe pneumonia.\n* Treatment with oral or IV antibiotics within 2 weeks prior to initiation of study treatment (Cycle 1, Day 1).\n* Has not adequately recovered from major surgery or has ongoing surgical complications.\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting 3 months before Cycle 1 Day 1 and continuing for at least 6 months for male subjects and 7 months for female subjects after the last dose.\n* Female participants must be at least 1 year post-menopausal, surgically sterile, or using at least 1 highly effective form of birth control (a highly effective method of contraception is defined as one that can achieve a failure rate of less than 1% per year when used consistently and correctly.) Women of childbearing potential who are sexually active with a non-sterilized male partner must agree to use at least 1 highly effective method of birth control. They should have been stable on their chosen method of birth control for a minimum of 3 months before Cycle 1 Day 1 and continue for at least 7 months after the last dose. Female participants must refrain from egg cell donation or retrieval for their own use, and breastfeeding from first dose throughout the study and for at least 7 months after the last dose of study drug. Any non-sterilized male partner of a woman of childbearing potential must use a male condom plus spermicide (condom alone in countries where spermicides are not approved) throughout this period.\n* Male participants who intend to be sexually active with a female partner of childbearing potential must be surgically sterile or use an acceptable method of contraception from the time of screening throughout the total duration of the study and the drug washout period (at least 6 months after the last dose of study intervention), in addition to the female partner using a highly effective contraceptive method, to prevent pregnancy in a partner. Male participants must not donate or bank sperm during this same time period. Preservation of sperm should be considered prior to inclusion. Not engaging in heterosexual activity (sexual abstinence) for the duration of the study and drug washout period is an acceptable practice, if this is the preferred usual lifestyle of the participant. Periodic or occasional abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception.\n* Has had an allogenic tissue\u002Fsolid organ transplant.",{"count":418,"type":21},46,[125],"This is a Phase II, single-arm, multicenter trial for patients with metastatic non-small cell lung cancer who have brain metastases and no known actionable mutations. Eligible patients will receive a combination of Datopotamab-deruxtecan, Carboplatin, and Pembrolizumab every three weeks for four cycles, followed by maintenance therapy with Datopotamab-deruxtecan and Pembrolizumab until disease progression or intolerable toxicity. Patients with intracranial progression but no systemic progression may receive stereotactic radiosurgery and continue treatment based on the investigator's decision.",[26,422,423],"Non Small Cell Lung Cancer","Brain Metastases",{"date":174,"type":43},{"date":426,"type":43},"2025-09-12",{"date":428,"type":21},"2028-11-01",{"name":430,"class":50},"Latin American Cooperative Oncology Group",13,{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":4,"eligibilityCriteria":438,"healthyVolunteers":94,"sex":17,"minAge":439,"maxAge":440,"enrollmentInfo":441,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":442,"conditions":443,"keywords":444,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":454},"100645529","a-study-of-lung-cancer-risk-100645529","NCT07701733","A Study of Lung Cancer Risk","ARISE: Assessing Lung Cancer Risk in Never-Smoking Women","Criteria:\n\n* Female at birth\n* Age 40-74 years\n* No smoking history\n\n  * Participants must be never-smokers, defined as having smoked \\\u003C100 cigarettes in their lifetime\n* Documentation of disease - case patients\n\n  o Case patients must have pathologically confirmed primary lung adenocarcinoma. New and prevalent cases will be eligible. Case patients with a history of prior non-lung cancer will be eligible for the study unless actively being diagnosed or treated for another form of cancer at the time of enrollment.\n* Criteria for control participants\n\n  * Control participants must have no personal history of lung cancer, symptoms suspicious for lung cancer, or suspicious pulmonary nodules. Participants recruited as controls and found on imaging to have lesions suspicious for lung cancer will be excluded from analysis and followed prospectively. Data regarding these participants will be reported in a sensitivity analysis. Additional control participants will be recruited to ensure balanced age- and race-matched enrollment by frequency matching. Control participants with a history of prior non-lung cancer will be eligible for the study unless actively being diagnosed or treated for another form of cancer at the time of enrollment.","40 Years","74 Years",{"count":358,"type":21},"The researchers are doing this study to learn more about factors that may increase the risk of lung cancer in people who have never smoked. This information may help predict which people who have never smoked may be more likely to get lung cancer.",[26],[445],"26-239","2026-08-13",{"date":371,"type":43},{"date":449,"type":43},"2026-06-30",{"date":451,"type":21},"2029-06",{"name":453,"class":50},"Memorial Sloan Kettering Cancer Center",7,{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":4,"eligibilityCriteria":461,"healthyVolunteers":94,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":462,"targetDuration":464,"studyType":22,"phases":4,"briefSummary":465,"conditions":466,"keywords":497,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":502,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":51},"100474891","inadvance-surveillance-prevention-and-interception-in-a-population-at-risk-for-cancer-100474891","NCT05463796","InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer","InAdvance: Surveillance, Prevention, and Interception in a Population at Risk For Cancer","Inclusion Criteria:\n\n* Participants to be included in this study include the following (note that this list is not comprehensive but gives examples of precursor conditions for each organ type):\n\n  1-Hereditary risk for cancer including\n  * Carriers of known or previously unrecognized pathogenic germline variants of cancer predisposing genes\n  * Individuals with personal or family history suggestive of elevated cancer risk (this may include individuals who have negative genetic testing results or have not elected to undergo testing)\n  * Individuals with a clinically based diagnosis of a Cancer Predisposition Syndrome (examples, neurofibromatosis, Fanconi Anemia, Ataxia-Telangiectasia)\n  * Hereditary Cancer Prediction Model-based elevated cancer risk\n  * Others at risk for specific cancers by virtue of exposure, obesity, gender, race and ethnicity, HPV exposure (for H\\&N cancer for example), etc.\n* Exposed High Risk including\n\n  * Childhood cancer survivors with treatment exposures associated with increased risk of cancer\n  * Adult cancer survivors with treatment exposures associated with increased risk of cancer\n  * Documented high level exposure to group 1 IARC carcinogens\n  * Thoracic: individuals at risk for lung cancer including but not exclusive of the following criteria: Age \\>50, Smoking history of \\>15 pack years, First-degree relative history of lung cancer or COPD\n  * alcoholic liver disease (NAFL), non-alcoholic steatohepatitis (NASH), cirrhosis\n* Precursor Lesions including\n\n  * Breast: ductal\u002Flobular carcinoma in situ (CIS) and atypical hyperplasia\n  * GI: Barrett's esophagus, Pancreatic precursor lesions, colonic dysplasia\u002Fadenomata, nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), cirrhosis\n  * GU: High grade prostatic epithelial neoplasia, and high-grade bladder urothelial dysplasia\u002Fcarcinoma in situ,\n  * Lung: Adenomatous hyperplasia\n  * H\\&N: high-risk oral precancerous diseases\n  * Skin: Class II melanocytic lesions. Squamous dysplasia\n  * Heme malignancies: CHIP, CCUS, ICUS, MGUS, SMM, SWM, MBL (spell these out), Low grade lymphomas\n  * Thoracic: Lung nodules detected on screening CT that prompt further follow-up\n  * GYN: STIC lesion (serous tubal intraepithelial carcinoma), Endometrial intraepithelial neoplasia, Cervical and endocervical carcinoma in situ, vulvar intraepithelial neoplasia\n  * Pediatric histologic diagnoses sometimes associated with development of malignancy: Nephrogenic rests, benign bone lesions with risk of malignant degeneration (Giant cell tumor, osteochondroma), Spitz nevus, and others.\n* FAMILY MEMBERS or healthy individuals\n\nExclusion Criteria:\n\nThere are no exclusion criteria for the study.\n\nNote: Patients with prior cancer history are allowed to participate. Patients with prior history of cancer or non-metastatic localized cancers (such as skin cancer or localized prostate cancer) are allowed to be enrolled. Patients enrolled in clinical trials or receiving therapy for precursor diseases are NOT excluded from this study.",{"count":463,"type":21},5000,"20 Years","This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member who has a family member with a precursor condition for cancer.\n\n* The objective of this study is to identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of progression to symptomatic cancer that can ultimately be fatal.\n* The ultimate goal is to identify novel markers of early detection and risk stratification to drive potential therapeutic approaches to intercept progression to cancer.",[467,468,469,470,471,472,473,26,474,475,476,477,478,479,480,481,482,483,484,485,486,487,488,489,490,491,492,493,494,495,496],"Cancer Risk","Cancer Predisposition Syndrome","Hereditary Cancer Prediction","Childhood Cancer Survivors","Adult Cancer Survivors","IARC Carcinogens","Smoking History","Ductal\u002FLobular Carcinoma","Barrett Esophagus","Pancreatic Precursor Lesions","Colonic Dysplasia\u002FAdenomata","Non-Alcoholic Fatty Liver Disease","Non Alcoholic Steatohepatitis","Cirrhosis","High Grade Prostatic Epithelial Neoplasia","High-grade Bladder Urothelial Dysplasia\u002FCarcinoma in Situ","Adenomatous Hyperplasia","High-risk Oral Precancerous Diseases","Melanocytic Lesion, Adult","Hematologic Malignancy","Lung; Node","Serous Tubal Intraepithelial Carcinoma","Endometrial Intraepithelial Neoplasia","Cervical and Endocervical Carcinoma in Situ","Vulvar Intraepithelial Neoplasia","Nephrogenic Rests","Benign Bone Lesions With Risk of Malignant Degeneration","Giant Cell Tumor","Osteochondroma","Spitz Nevus",[498,499,500,501],"Hereditary Risk for Cancer","Childhood cancer survivors","Adult cancer survivors","Precursor Lesions",{"date":223,"type":43},{"date":504,"type":43},"2023-04-25",{"date":506,"type":21},"2031-03-25",{"name":508,"class":50},"Dana-Farber Cancer Institute",{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":513,"acronym":514,"eligibilityCriteria":515,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":516,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":518,"conditions":519,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":526,"locationsCount":528},"100638987","real-world-outcomes-of-resected-egfr-mutated-nsclc-patients-treated-with-adjuvant-egfr-tki-in-china-100638987","NCT07593248","Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China","ECHO","Inclusion Criteria:\n\n* Diagnosed stage IB-III NSCLC on or prior to the index date;\n* Initiated adjuvant EGFR-TKI from July 1st, 2023 to June 30th, 2026",{"count":517,"type":21},2000,"This is a multi-centre, observational study, with retrospective data collection and prospective active follow-up. The aim is to measure the treatment pattern and real-world outcomes of EGFR-TKI as an adjuvant therapy in patients with early-stage EGFR-mutated NSCLC. The study period ranges from July 1st, 2022 to June 30th, 2031. Approximately 2,000 patients will be enrolled from 15 sites in China.",[26],"2026-08-12",{"date":446,"type":43},{"date":523,"type":43},"2026-06-22",{"date":525,"type":21},"2031-06-30",{"name":527,"class":152},"AstraZeneca",14,{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":4,"eligibilityCriteria":535,"healthyVolunteers":94,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":536,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":538,"conditions":539,"keywords":542,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":548,"startDateStruct":549,"completionDateStruct":4,"leadSponsor":551,"locationsCount":51},"100060621","collection-of-blood-from-patients-with-cancer-100060621","NCT00034216","Collection of Blood From Patients With Cancer","Biospecimen Acquisition From Human Subjects","* INCLUSION CRITERIA:\n\nPatients with a known or suspected malignancy and healthy volunteers 18 years of age and older are eligible.\n\nPerformance status of ECOG 0, 1, 2, or 3 for admission to this protocol.\n\nAbility to understand and the willingness to sign a written informed consent document.\n\nINCLUSION FOR APHERESIS:\n\nNote: Effective with Amendment CC, participants will no longer be asked to undergo apheresis. This content is being retained for historical reference.\n\nHemoglobin greater than or equal to 10 mg\u002FdL and platelet count \\> 75,000\u002Fmm(3)\n\nWeight greater than 25 kg\n\nHIV negative\n\nProthrombin Time - within normal limits\n\nPartial Thromboplastin Time - within normal limits\n\nMedically indicated central line in place or adequate peripheral venous access\n\nEXCLUSION CRITERIA:\n\nNone.",{"count":537,"type":21},1750,"This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate. This study does not involve treatment.\n\nParticipants will have about 50 ml (3 tablespoonfuls) of blood drawn. Depending on their condition, patients may be invited to enroll in a clinical research study involving chemotherapy, radiotherapy, or surgery. Additional 40-ml blood samples may be drawn during the course of treatment.",[71,25,540,26,541],"Colon Cancer","Liver Cancer",[543,544,545,322,323,546,547],"Suppressor Cells","T-cells","CD4+ \u002F CD25+ cells","Malignancy","Blood Sample",{"date":446,"type":43},{"date":550,"type":43},"2002-07-16",{"name":329,"class":330},{"id":553,"slug":554,"hasResults":12,"nctId":555,"briefTitle":556,"officialTitle":557,"acronym":4,"eligibilityCriteria":558,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":559,"targetDuration":4,"studyType":62,"phases":560,"briefSummary":561,"conditions":562,"keywords":563,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":566,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":454},"100582432","phase-1-a-study-of-cd8-t-cell-imaging-during-treatment-in-people-with-non-small-cell-lung-cancer-100582432","NCT06863233","A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer","Assessment of Patients Immune Response After Treatment With Engineered Tumor Infiltrating Lymphocyte Therapy Incorporating CD8 PET Imaging","Inclusion Criteria:\n\n* Patient must be 18 years of age or older at the time of signing the informed consent.\n* Patient has a histologically confirmed diagnosis of metastatic non-small cell lung cancer\n* Patient is enrolled in the engineered TIL cell therapy protocol OBX115-23-01, but has not received the treatment yet.\n* Men and women of child-producing potential, use of effective double barrier contraceptive methods during the study, up to 30 days after the last administration of the investigational product.\n* Patient or legally authorized representative provided signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n* Patient or legally authorized representative provided written authorization for use and disclosure of protected health information.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Patients with a history of splenectomy or significant splenic dysfunction (e.g., as evidenced by splenomegaly or a history of recurrent infections due to impaired immune function)",{"count":182,"type":21},[241],"The purpose of this study to learn whether PET\u002FCT (positron emission tomography\u002Fcomputed tomography) scans using an imaging agent (radiotracer) called zirconium Zr 89 crefmirlimab berdoxam is a safe and effective way to identify CD8+ T cells",[26,422,396],[26,422,396,453,564],"24-369","2026-08-11",{"date":446,"type":43},{"date":568,"type":43},"2025-03-03",{"date":570,"type":21},"2028-03-03",{"name":453,"class":50},{"id":573,"slug":574,"hasResults":12,"nctId":575,"briefTitle":576,"officialTitle":577,"acronym":578,"eligibilityCriteria":579,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":580,"enrollmentInfo":581,"targetDuration":4,"studyType":62,"phases":582,"briefSummary":583,"conditions":584,"keywords":588,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":598,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":51},"100651415","68ga-sorb-petct-imaging-in-patients-with-solid-tumors-100651415","NCT07760012","68Ga-SorB PET\u002FCT Imaging in Patients With Solid Tumors","A Prospective, Single-Center, Open-Label Exploratory Study of 68Ga-SorB PET\u002FCT Imaging for the Diagnosis of Sortilin-Positive Solid Tumors","SORB-PET","Inclusion Criteria:\n\n* \\- Adults aged 18 to 75 years.\n* Histologically confirmed or clinically suspected melanoma, hepatocellular carcinoma, lung cancer, breast cancer, pancreatic cancer, or ovarian cancer.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate hematologic, hepatic, renal, and coagulation function:\n* White blood cell count ≥ 4.0 × 10\\^9\u002FL or absolute neutrophil count ≥ 1.5 × 10\\^9\u002FL;\n* Platelet count ≥ 100 × 10\\^9\u002FL;\n* Hemoglobin ≥ 90 g\u002FL;\n* PT or APTT ≤ 1.5 × upper limit of normal (ULN);\n* Total bilirubin ≤ 1.5 × ULN;\n* ALT and AST ≤ 2.5 × ULN (or ≤ 5 × ULN for participants with liver metastases);\n* ALP ≤ 2.5 × ULN (or ≤ 4.5 × ULN for participants with bone or liver metastases);\n* Blood urea nitrogen and serum creatinine ≤ 1.5 × ULN.\n* Normal cardiac function.\n* Estimated life expectancy of at least 12 weeks.\n* Willing and able to comply with study procedures and follow-up.\n* At least one measurable target lesion according to RECIST version 1.1.\n* Participants of childbearing potential agree to use effective contraception during the study and for 3 months after PET\u002FCT imaging.\n* Clinically indicated to undergo 18F-FDG PET\u002FCT for tumor evaluation.\n* Able to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women.\n* Severe dysfunction of major organs (including heart, liver, or kidney) that, in the investigator's judgment, would make participation inappropriate.\n* Inability to tolerate PET\u002FCT imaging or complete study follow-up.\n* Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.","75 Years",{"count":61,"type":21},[64],"This prospective, single-center, open-label exploratory diagnostic study aims to evaluate the safety, feasibility, and diagnostic performance of the novel Sortilin-targeted PET tracer 68Ga-SorB in patients with solid tumors. Eligible participants with confirmed or suspected melanoma, hepatocellular carcinoma, lung cancer, pancreatic cancer, breast cancer, or ovarian cancer will undergo 68Ga-SorB PET\u002FCT imaging. The imaging findings will be compared with standard-of-care 18F-FDG PET\u002FCT, using pathology results and\u002For clinical follow-up as the reference standard.\n\nThe primary objectives are to evaluate the safety and tolerability of 68Ga-SorB, assess imaging feasibility, and characterize tumor uptake using quantitative PET parameters, including SUVmax and tumor-to-background ratio (TBR). Secondary exploratory objectives include comparing lesion detection between 68Ga-SorB PET\u002FCT and 18F-FDG PET\u002FCT, assessing diagnostic sensitivity and specificity, evaluating imaging characteristics across different tumor types, and exploring the correlation between Sortilin expression and tracer uptake. This study will provide preliminary clinical evidence supporting the development of Sortilin-targeted molecular imaging and future theranostic applications.",[585,586,26,25,587,314],"Melanoma (Skin Cancer)","Hepatocellular Carcinoma","Pancreatic Cancer",[589,590,591,592,593,594,595,596],"Sortilin","68Ga-SorB","PET\u002FCT","Molecular Imaging","Diagnostic Imaging","Positron Emission Tomography","Radiotracer","Oncology","2026-08-09",{"date":520,"type":43},{"date":600,"type":21},"2026-07-24",{"date":602,"type":21},"2028-12-31",{"name":604,"class":50},"Peking University Third Hospital",{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":609,"acronym":4,"eligibilityCriteria":610,"healthyVolunteers":94,"sex":17,"minAge":464,"maxAge":4,"enrollmentInfo":611,"targetDuration":4,"studyType":62,"phases":613,"briefSummary":614,"conditions":615,"keywords":617,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":628,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":51},"100604211","evaluating-the-implementation-and-effectiveness-of-the-pink-and-pearl-campaign-on-lung-cancer-screening-at-christian-hospital-100604211","NCT07146568","Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hospital","Eligibility Criteria - Interventional Study\n\n* Undergoing screening mammography at Christian Hospital\n* Between the ages of 50-80 years (inclusive)\n\nEligibility Criteria - Survey and Interview Sub-Studies\n\n* Part of the interventional study\n* Reporting a 20 pack-year equivalent of either current smoking history or have quit in the past 15 years\n* Can speak and understand English\n* Not diagnosed with a serious health problem that will limit life expectancy (such as previous history of lung cancer, symptoms of lung cancer such as hemoptysis or unexplained weight loss of more than 6.8 kg (15 lb) in the previous year)\n* Willing and able to get treatment if lung cancer is found\n* Able to understand and willing to sign an IRB-approved written informed consent document\n\nEligibility Criteria - Providers\n\n* At least 20 years of age\n* Involved in the breast radiology service or referred at least one patient to the Pink \\& Pearl Campaign\n* Able to provide verbal consent to participate in the interview",{"count":612,"type":21},5515,[64],"Inspired by the ongoing Pink \\& Pearl Campaign, the breast radiology service of Christian Hospital in north St. Louis County will partner with Siteman Cancer Center to pilot this campaign in its mammography clinics in order to promote awareness, referral, and completion of lung cancer screening (LCS) among eligible women. This campaign leverages established infrastructure such as nurse navigation and referral to screening or primary care for further shared decision-making on cancer screening. The purpose of this study is to evaluate the effectiveness of the Pink \\& Pearl Campaign in improving LCS uptake among LCS-eligible women undergoing mammography at Christian Hospital. This evaluation is grounded in the Integrated Screening Action Model that depicts individual- and environmental-level influences on the screening behavior process. Using an explanatory sequential mixed methods design, which combines both quantitative and qualitative approaches, our specific aims for this proposal are to: a) assess whether the Pink \\& Pearl Campaign increases referrals and uptake\u002Fcompletion of LCS among LCS-eligible women undergoing screening mammography; b) determine median time-to-screening after referral to LCS; and c) evaluate individual and health system factors influencing LCS uptake and implementation outcomes of the campaign. These implementation outcomes will help identify whether the campaign was put in place successfully or not. This proposal will inform strategies for integrating cancer screening programs to improve poorly performing programs like LCS.",[26,616],"Cancer of the Lung",[618,619,620,621,622,623,624,625,626,627],"Lung cancer screening (LCS)","Pink and Pearl Campaign","Breast cancer screening (BCS)","Low-dose computed tomography (LDCT)","Smoking history","Health disparities","Screening behavior","Feasibility","Acceptability","Appropriateness",{"date":520,"type":43},{"date":630,"type":43},"2026-02-23",{"date":632,"type":21},"2027-02-28",{"name":634,"class":50},"Washington University School of Medicine",{"id":636,"slug":637,"hasResults":12,"nctId":638,"briefTitle":639,"officialTitle":640,"acronym":4,"eligibilityCriteria":641,"healthyVolunteers":94,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":642,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":644,"conditions":645,"keywords":646,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":647,"startDateStruct":648,"completionDateStruct":650,"leadSponsor":652,"locationsCount":51},"100585128","implementation-and-effectiveness-of-the-bjc-pink-and-pearl-project-on-lung-cancer-screening-100585128","NCT06898333","Implementation and Effectiveness of the BJC-Pink and Pearl Project on Lung Cancer Screening","Evaluating the Implementation and Effectiveness of the BJC-Pink and Pearl Project on Lung Cancer Screening","Inclusion Criteria for Participants:\n\n* Undergoing screening mammography\n* Between the ages of 50-80 years (inclusive)\n* Reporting a 20 pack-year equivalent of either current smoking history or have quit in the past 15 years\n* Can speak and understand English\n* Ability to understand willingness to provide informed consent.\n\nExclusion Criteria for Participants:\n\n* Diagnosed with a serious health problem that will likely limit life expectancy (such as previous history of lung cancer, symptoms of lung cancer such as hemoptysis or unexplained weight loss of more than 6.8 kg (15 lb) in the previous year)\n\n  * Subjects with symptoms of lung cancer should get a diagnostic CT scan\n* Unable or unwilling to get treatment if lung cancer is found\n\nEligibility Criteria for Providers:\n\n* Older than 20 years of age",{"count":643,"type":21},279,"The investigators proposal is ripe for executing as the investigators seek to leverage this \"natural experiment\" initiated by the BJC health system to evaluate the effectiveness of the Pink \\& Pearl Campaign as an implementation strategy to promote lung cancer screening (LCS) uptake among LCS-eligible women undergoing mammography at BJC West County. This evaluation is grounded in the Integrated Screening Action Model that depicts individual- and environmental-level influences on the screening behavior process. Using an explanatory sequential mixed methods design, which combines both quantitative and qualitative approaches, the research questions and specific aims for this proposal are to: a) evaluate the baseline prevalence of LCS among LCS-eligible women; b) assess whether the Pink \\& Pearl Campaign increases referrals and uptake\u002F completion of LCS among LCS-eligible women undergoing screening mammography; and c) evaluate individual and environmental factors influencing LCS uptake, and implementation outcomes of the campaign. These implementation outcomes will help identify whether the campaign was put in place successfully or not. This proposal will inform strategies for integrating cancer screening programs to improve poorly performing programs like LCS.",[26,616],[618,619,620,621,622,623,624,625,626,627],{"date":520,"type":43},{"date":649,"type":43},"2025-05-08",{"date":651,"type":21},"2027-05-31",{"name":634,"class":50},{"id":654,"slug":655,"hasResults":12,"nctId":656,"briefTitle":657,"officialTitle":657,"acronym":658,"eligibilityCriteria":659,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":660,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":661,"conditions":662,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":597,"lastUpdatePostDateStruct":663,"startDateStruct":664,"completionDateStruct":666,"leadSponsor":668,"locationsCount":205},"100330126","genomic-analysis-to-identify-a-predictive-biomarker-for-immunotherapy-100330126","NCT03578185","Genomic Analysis to Identify a Predictive Biomarker for Immunotherapy","LC_Biomarker","Inclusion Criteria:\n\n1. aged above or equal to 18\n2. Histologically confirmed lung cancer patients\n3. Patient treated with immune checkpoint inhibitor\n\nExculsion Criteria:\n\nNA",{"count":517,"type":21},"This study is designed to identify the predictive biomarker for immunotherapy using patient samples (tumor tissue, blood, fecal material) who treated with immune checkpoint inhibitor.",[26],{"date":520,"type":43},{"date":665,"type":43},"2018-04-11",{"date":667,"type":21},"2030-12-31",{"name":669,"class":50},"Samsung Medical Center",{"id":671,"slug":672,"hasResults":12,"nctId":673,"briefTitle":674,"officialTitle":675,"acronym":4,"eligibilityCriteria":676,"healthyVolunteers":12,"sex":17,"minAge":677,"maxAge":4,"enrollmentInfo":678,"targetDuration":4,"studyType":62,"phases":679,"briefSummary":680,"conditions":681,"keywords":703,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":732,"lastUpdatePostDateStruct":733,"startDateStruct":735,"completionDateStruct":737,"leadSponsor":739,"locationsCount":741},"100407463","the-evaluation-of-pc14586-in-patients-with-advanced-solid-tumors-harboring-a-tp53-y220c-mutation-pynnacle-100407463","NCT04585750","The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","A Phase 1\u002F2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","Inclusion Criteria:\n\n* At least 18 years of age or 12 to 17 years of age after Safety Review Committee approval.\n* Locally advanced or metastatic solid malignancy with a TP53 Y220C mutation\n* Eastern Cooperative Oncology Group (ECOG) status of 0 or 1\n* Previously treated with one or more lines of anticancer therapy and progressive disease\n* Adequate organ function\n* Measurable disease per RECIST v1.1 (Phase 2)\n\nAdditional Criteria for Inclusion in Phase 1b (rezatapopt) + pembrolizumab combination)\n\n* Anti-PD-1\u002FPD-L1 naive or must have progressed on treatment\n* Measurable disease\n\nExclusion Criteria:\n\n* Anti-cancer therapy within 21 days (or 5 half-lives) of receiving the study drug\n* Radiotherapy within 14 days of receiving the study drug\n* Primary CNS tumor\n* History of leptomeningeal disease or spinal cord compression\n* Brain metastases, unless neurologically stable and do not require steroids to treat associated neurological symptoms\n* Stroke or transient ischemic attack within 6 months prior to screening\n* Heart conditions such as unstable angina within 6 months prior to screening, uncontrolled hypertension, a heart attack within 6 months prior to screening, congestive heart failure, prolongation of QT interval, or other rhythm abnormalities\n* Strong CYP3A4 inducers and strong CYP2C9 inhibitors\u002Finducers within 14 days of first dose of rezatapopt\n* History of gastrointestinal (GI) disease that may interfere with absorption of study drug or patients unable to take oral medication\n* History of prior organ transplant\n* Known, active malignancy, except for treated cervical intraepithelial neoplasia, or non-melanoma skin cancer\n* Known, active uncontrolled Hepatitis B, Hepatitis C, or human immunodeficiency virus infection\n\nAdditional Criteria for Exclusion from Phase 2 (rezatapopt monotherapy)\n\n* Known KRAS mutation, defined as a single nucleotide variant (SNV) (Phase 2)\n\nAdditional Criteria for Exclusion from Phase 1b (rezatapopt) + pembrolizumab combination)\n\n* Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor and discontinued from that treatment due to a Grade 3 or higher immune-related AE (irAE)\n* Received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention\n* Diagnosis of immunodeficiency or receiving chronic systemic steroid therapy within 7 days prior to the first dose of study drug\n* Hypersensitivity (≥ Grade 3) to pembrolizumab and\u002For any of its excipients\n* Active autoimmune disease that has required systemic treatment in past 2 years\n* History of radiation pneumonitis\n* History of (non-infectious) or active pneumonitis \u002F interstitial lung disease that required steroids\n* Active infection requiring systemic therapy\n* Known history of HIV infection\n* Has previously received rezatapopt","12 Years",{"count":287,"type":21},[241,125],"The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.",[128,682,683,684,26,314,70,71,69,25,685,686,32,687,688,689,690,691,692,693,694,695,696,697,393,698,699,700,701,702],"Advanced Malignant Neoplasm","Metastatic Cancer","Metastatic Solid Tumor","Other Cancer","Locally Advanced","Gall Bladder Cancer","Small Cell Lung Cancer","Small Cell Lung Cancer ( SCLC )","Small Cell Lung Carcinoma","NSCLC","NSCLC (Non-small Cell Lung Cancer)","SCLC","Non-Small Cell Lung Carcinoma","Triple Negative Breast Cancer","TNBC","HER2+ Breast Cancer","ER\u002FPR Positive Breast Cancer","HER2- Breast Cancer","HER2-positive Breast Cancer","HER2-negative Breast Cancer","ER\u002FPR(+), Her2(-) Breast Cancer",[704,705,706,707,708,709,710,711,712,713,714,715,716,717,718,719,720,721,722,723,724,725,726,727,728,729,730,731],"PC14586","p53","Y220C","Phase 1","Phase 1\u002F2","PMV","PMV Pharma","p53 mutation","TP53","TP53 mutation","p53 mutant","p53 reactivator","pembrolizumab","Keytruda","combination","PD-1","PD-L1","anti-PD-1","Merck","MSD","IgG4","mAb","Phase 1b","NGS","Next Generation Sequencing","precision","Phase 2","Rezatapopt","2026-08-07",{"date":734,"type":43},"2026-08-10",{"date":736,"type":43},"2020-10-29",{"date":738,"type":21},"2027-12-31",{"name":740,"class":152},"PMV Pharmaceuticals, Inc",77]